Vaxcyte Files 8K - Entry Into Definitive Agreement >PCVX

Vaxcyte Inc. (PCVX) filed a Form 8K - Entry Into a Definitive Agreement - with the U.S Securities and Exchange Commission on October 09, 2026. On October 9, 2026, Vaxcyte, Inc. ("Vaxcyte") consummated the sale and issuance of $575,000,000 aggregate principal amount of its 1.50% Convertible Senior Notes due 2032 (the "Notes") to certain underwriters (the "Debt Offering"). The Notes were issued pursuant to, and are governed by, an indenture (the "Base Indenture"), dated as of October 9, 2026, between Vaxcyte and U.S. Bank Trust Company, National Association, as trustee (the "Trustee"), as supplemented by a First Supplemental Indenture (the "Supplemental Indenture," and the Base Indenture, as supplemented by the Supplemental Indenture, the "Indenture"), dated as of October 9, 2026, between Vaxcyte and the Trustee. The Notes are senior, unsecured obligations and will accrue interest at a rate of 1.50% per annum, payable semi-annually in arrears on April 15 and October 15 of each year, beginning on April 15, 2027. The Notes will mature on October 15, 2032 unless earlier repurchased, redeemed or converted. Before July 15, 2032,.